All In MedTech

FDA Clearance Tracker · P210034

Agili-C

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 29, 2022 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Mar 29, 2022

Approved

Time to decision

180 days

Received Sep 30, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P210034
Device name
Agili-C
Applicant location
Andover, MA
Received
Sep 30, 2021
Decided
Mar 29, 2022
Decision
Approved
Supplements
1 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QRU

FDA's approval statement

As written in FDA's record.

Approval for Agili-C. The Agili-C scaffold is indicated for the treatment of an International Cartilage Repair Society (ICRS) grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2, without severe osteoarthritis (Kellgren-Lawrence grade 0-3).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QRU (Implant, resorbable, for articular osteochondral repair).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Smith and Nephew, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.